Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ribaxamase · SYN-004

Recombinant protein · Protein replacement: beta-lactam antibiotics (hydrolyzed in the intestine) · developed by Theriva Biologics

Phase 1/2 Most advanced trial (none active)
TOVX Developer
2 Registered trials

What is Ribaxamase?

Ribaxamase (SYN-004) is an orally administered recombinant beta-lactamase enzyme. It hydrolyzes the beta-lactam ring of intravenously given beta-lactam antibiotics that reach the intestine, aiming to protect the gut microbiome. It is studied in the context of Clostridium difficile infection and antibiotic-associated diarrhea.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SYN-004
Drug type
Recombinant protein
Targets
beta-lactam antibiotics (hydrolyzed in the intestine)
Mechanism
Protein replacement: beta-lactam antibiotics (hydrolyzed in the intestine)
Pathways
beta-lactam hydrolysis in the gastrointestinal tract, gut microbiome protection
Therapy area
Infectious disease
Developer
Theriva Biologics, Inc. (TOVX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
6A002O1K0R

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02563106 Phase 2 Clostridium Difficile Completed TOVX
NCT02419001 Phase 1/2 Healthy Volunteers Completed TOVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clostridium DifficileClostridium InfectionsHealthy Volunteers

More from Theriva Biologics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TOVX page.

Follow TOVX, the company behind Ribaxamase

See TOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TOVX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.